EOLS News and Press, Evolus Inc. From 03/26/24

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conference in April: Event: The 23 rd Annual Needham Virtual Healthcare Conference Date...

2024-03-20 14:05:03 ET Summary Evolus, a global performance beauty company, raised $60m in its IPO in 2018. Its first and only commercial product, Jeuveau, is an injectable botulinum toxin Type A product that has been approved in the US and most European territories. Evolus ha...

2024-03-17 17:09:16 ET More on AbbVie, Evolus, etc. AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript) AbbVie: Comeback Expected After Humira Patent Expiration AbbVie Stock: I Was So Wrong, But This Is Way Too Fast Evolus prices...

2024-03-12 04:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-11 07:24:26 ET More on Evolus Evolus: Negative Earnings Continue Despite Sustained Top-Line Growth Evolus GAAP EPS of -$0.21 in-line, revenue of $61M in-line Evolus, Alvotech gain as Barclays raises to Ovrweight Read the full article on Seeking Alph...

Evolus, Inc. (Nasdaq: EOLS) announced today the pricing of its underwritten offering of 3,554,000 shares of its common stock at a underwritten offering price of $14.07 per share, which is equal to the closing price on Friday, March 8, 2024, before underwriting discounts and commissions. The gro...

2024-03-07 22:40:28 ET Evolus, Inc. (EOLS) Q4 2023 Earnings Conference Call March 07, 2024, 04:30 PM ET Company Participants Nareg Sagherian - VP and Head of Global Investor Relations and Corporate Communications David Moatazedi - President and CEO Rui Avelar - C...

2024-03-07 16:26:41 ET More on Evolus Evolus: Negative Earnings Continue Despite Sustained Top-Line Growth Evolus, Alvotech gain as Barclays raises to Ovrweight Evolus shares rise on upbeat 2024 revenue outlook Seeking Alpha’s Quant Rating on Evolus ...

Generated $0.8M of Cash from Operating Activities in Q4 2023 Recorded Lowest Quarter of Non-GAAP Operating Loss Since Inception, Non-GAAP Operating Loss for Q4 is $3.7 Million, an Improvement of $2 Million Compared to Q3 Full Year 2023 Operating Expense of $163.9 Million in Alignm...

Gevo Inc. (GEVO) is expected to report $-0.05 for Q4 2023 Harvard Bioscience Inc. (HBIO) is expected to report $0.03 for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 DFI Retail Group Holdings Limited ADR (DFIHY) is expected to report for quarter end 2...